Design and evaluation of self-emulsifying drug delivery systems (SEDDS) of nimodipine

AAPS PharmSciTech

Volumn 9, Issue 1, 2008, Pages 191-196

  Kale, Amit A ^a   Patravale, Vandana B ^a  

^a INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

In vitro drug release; Low oral bioavailability; Nimodipine; Pharmacokinetics; Self emulsifying drug delivery systems (SEDDS)

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; COSURFACTANT; NIMODIPINE; OIL; SURFACTANT; DRUG CARRIER;

ANIMAL EXPERIMENT; AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISSOLUTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG RELEASE; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; DRUG STORAGE; EMULSION; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MICELLE; NONHUMAN; PARTICLE SIZE; PH; PHOTON CORRELATION SPECTROSCOPY; RABBIT; SELF EMULSIFYING DRUG DELIVERY SYSTEM; SUSPENSION; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; CHEMISTRY; DIFFUSION; EVALUATION; MATERIALS TESTING; METHODOLOGY; SOLUBILITY;

ANIMALS; CALCIUM CHANNEL BLOCKERS; DIFFUSION; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; EMULSIONS; MALE; MATERIALS TESTING; NIMODIPINE; OILS; RABBITS; SOLUBILITY; SURFACE-ACTIVE AGENTS;

EID: 44849119532     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-008-9037-9     Document Type: Article

References (21)

1. H. J. Gelmers. Calcium-channel blockers in the treatment of migraine. Am. J. Cardiol. 55: 139B-143B (1985).
2. M. S. Langley, and E. M. Sorkin. Nimodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic. Drugs 37: 669-699 (1989).
3. J. T. Zhang. Altered calcium homeostasis in brain aging and senile dementia, new approach to treat Alzheimer's disease. Yao Xue Xue Bao 28: 641-646 (1993).
4. L. Pantoni, R. Rossi, D. Inzitari, C. Bianchi, M. Beneke, T. Erkinjuntti, and T. Wallin. Efficacy and safety of nimodipine in subcortical vascular dementia: A subgroup analysis of the Scandinavian Multi-Infarct Dementia Trial. J. Neurol. Sci. 175: 124-134 (2000).
5. W. Muck, H. P. Breuel, and J. Kuhlmann. The influence of age on the pharmacokinetics of nimodipine. Int. J. Clin. Pharmacol. 34: 293-298 (1996).
6. P. Blardi, R. Urso, A. De Lalla, L. Volpi, T. D. Perri, and A. Auteri. Nimodipine: Drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia. Clin. Pharmacol. Ther. 72: 556-561 (2002).
7. D. Yang, J. Zhu, Y. Zheng, and L. Ge. Preparation, characterization, and pharmacokinetics of sterically stabilized nimodipine-containing liposomes. Drug Dev. Ind. Pharm. 32: 219-227 (2006).
8. R. G. Strickley. Solubilizing excipients in oral and injectable formulations. Pharm. Res. 21: 201-230 (2004).
9. M. J. Lawrence, and G. D. Rees. Microemulsion-based media as novel drug delivery systems. Adv. Drug Deliv. Rev. 45: 89-121 (2000).
10. R. N. Gursoy, and S. Benita. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed. Pharmacother. 58: 173-182 (2004).
11. A. J. Humberstone, and W. N. Charman. Lipid-based vehicles for the oral delivery of poorly water soluble drugs. Adv. Drug Deliv. Rev. 25: 103-128 (1997).
12. C. M. O'Driscoll. Lipid-based formulations for intestinal lymphatic delivery. Eur. J. Pharm. Sci. 15: 405-415 (2002).
13. G. Cornaire, J. Woodley, P. Hermann, A. Cloarec, C. Arellano, and G. Houin. Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. Int. J. Pharm. 278: 119-131 (2004).
14. X. Sha, G. Yan, Y. Wu, J. Li, and X. Fang. Effect of self-microemulsifying drug delivery systems containing Labrasol on tight junctions in Caco-2 cells. Eur. J. Pharm. Sci. 24: 477-486 (2005).
15. L. Wei, P. Sun, S. Nie, and W. Pan. Preparation and evaluation of SEDDS and SMEDDS containing carvedilol. Drug Dev. Ind. Pharm. 31: 785-794 (2005).
16. M. Qian, and J. Gallo. HPLC determination of calcium channel blocker nimodipine in monkey plasma. J. Chromatogr. 578: 316-320 (1992).
17. S. A. Barker, S. P. Yap, K. H. Yuen, C. P. McCoy, J. R. Murphy, and D. Q. M Craig. An investigation into the structure and bioavailability of α-tocopherol dispersions in Gelucire 44/14. J. Control Rel. 91: 477-488 (2003).
18. N. Yuksel, A. Karatas, Y. Ozkan, A. Savaser, S. Ozkan, and T. Baykara. Enhanced bioavailability of piroxicam using Gelucire 44/14 and Labrasol: in vitro and in vivo evaluation. Eur. J. Pharm. Biopharm. 56: 453-459 (2003).
19. H. J. Kim, K. A. Yoon, M. Hahn, E. S. Park, and S. C. Chi. Preparation and in vitro evaluation of self-microemulsifying drug delivery systems containing idebenone. Drug Dev. Ind. Pharm. 26: 523-529 (2000).
20. C. W. Pouton. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. Eur. J. Pharm. Sci. 11 Suppl. 2:S93-S98 (2000).
21. Z. Hu, R. Tawa, T. Konishi, N. Shibata, and K. Takada. A novel emulsifier, Labrasol, enhances gastrointestinal absorption of gentamicin. Life Sci. 69: 2899-2910 (2001).